FOXP1 and prostate adenocarcinoma: We find that FOXP1-SHQ1 deletion co-occurs more often than expected with loss of PTEN, a common tumor suppressor of the PI3K pathway, in primary prostate adenocarcinoma (Memorial Sloan Kettering cohort3, P = 0.008, Fisher’s exact test, Supplementary Table 1, Fig. 1a).